Fluticasone + Fluticason

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Allergy

Conditions

Allergy

Trial Timeline

Nov 1, 2010 → Jul 1, 2011

NCT ID

NCT01240889

About Fluticasone + Fluticason

Fluticasone + Fluticason is a pre-clinical stage product being developed by Roche for Allergy. The current trial status is completed. This product is registered under clinical trial identifier NCT01240889. Target conditions include Allergy.

What happened to similar drugs?

4 of 14 similar drugs in Allergy were approved

Approved (4) Terminated (3) Active (7)

✅Placebo + XolairNovartisApproved

✅OmalizumabNovartisApproved

✅Omalizumab InjectionRocheApproved

✅Fexofenadine HCISanofiApproved

❌ligelizumab + PlaceboNovartisPhase 3

❌Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3

🔄Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral ImmunotherapyNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01240889	Pre-clinical	Completed	Nov 1, 2010	Jul 1, 2011	Allergy

Competing Products

20 competing products in Allergy

See all competitors

Product	Company	Stage	Hype Score
ASP0892 Intradermal + ASP0892 Intramuscular + Placebo Intradermal + Placebo Intramuscular	Astellas Pharma	Phase 1	29
ASP0892 + Placebo	Astellas Pharma	Phase 1	29
Cetirizine 10mg + Cetirizine 10 mg + Cetirizine 10 mg	Johnson & Johnson	Phase 1	29
Cetirizine + Cetirizine	Johnson & Johnson	Phase 1	29
Acalabrutinib	AstraZeneca	Phase 2	35
Omalizumab	Novartis	Phase 1	29
ligelizumab + Placebo	Novartis	Phase 3	32
remibrutinib + placebo	Novartis	Phase 2	35
Placebo + Xolair	Novartis	Approved	39
QGE031 + Placebo	Novartis	Phase 2	27
Ligelizumab 120 mg + Ligelizumab 240 mg	Novartis	Phase 3	32
Omalizumab + Placebo for Omalizumab + Multi-Allergen Oral Immunotherapy + Placebo for Multi-Allergen Oral Immunotherapy	Novartis	Phase 3	40
QGE031 + Placebo	Novartis	Phase 1	29
Omalizumab	Novartis	Approved	43
Omalizumab Injection	Roche	Approved	50
Dupilumab + Placebo matching dupilumab + AR101	Sanofi	Phase 2	35
Fexofenadine HCI	Sanofi	Approved	43
Dupilumab	Sanofi	Phase 2	35
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PE	Sanofi	Phase 1	29
Dupilumab	Regeneron Pharmaceuticals	Pre-clinical	26